BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34547646)

  • 21. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
    Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
    Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
    Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
    Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
    Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and antitumor activity evaluation of trifluoromethyl-substituted pyrimidine derivatives.
    Liu L; Wang Z; Gao C; Dai H; Si X; Zhang Y; Meng Y; Zheng J; Ke Y; Liu H; Zhang Q
    Bioorg Med Chem Lett; 2021 Nov; 51():128268. PubMed ID: 34302974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
    Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
    Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
    Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X; Quan Y; Wang Y; Wang Y; Li Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
    Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.